Detalles de la búsqueda
1.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Blood
; 135(12): 912-920, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31978221
2.
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
J Cell Mol Med
; 18(8): 1519-39, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25100284
3.
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Lancet Oncol
; 13(3): 300-8, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22277837
4.
A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.
Clin Transl Med
; 13(11): e1471, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37962000
5.
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol
; 11(6): 521-9, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20493771
6.
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
J Cell Mol Med
; 14(1-2): 51-69, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20015198
7.
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Clin Cancer Res
; 14(12): 3867-74, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18559607
8.
Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69).
J Cell Mol Med
; 15(5): 1225, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21362132
9.
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Lung Cancer
; 98: 1-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27393499
10.
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
J Thorac Oncol
; 11(4): 545-55, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26773740
11.
ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.
J Pathol Clin Res
; 1(3): 134-43, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27499899
12.
Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.
Transl Lung Cancer Res
; 4(4): 465-74, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26380188
13.
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
J Thorac Oncol
; 10(9): 1364-1369, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26291013
14.
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Clin Cancer Res
; 21(14): 3196-203, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25829397
15.
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
J Thorac Oncol
; 9(9): 1411-7, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25122437
16.
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
PLoS One
; 9(2): e89518, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24586842
17.
Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.
Lung Cancer
; 82(2): 231-7, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23972450
18.
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Mol Cancer Ther
; 12(4): 520-9, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23371860
19.
Tissue sampling in lung cancer: a review in light of the MERIT experience.
Lung Cancer
; 74(1): 1-6, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21658788
20.
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
J Clin Oncol
; 27(8): 1268-74, 2009 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19204207
Resultados
1 -
20
de 20
1
Próxima >
>>